Skip to content
lifestyle.phenomena.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Faron Pharmaceuticals
Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026
February 23, 2026
Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML
February 19, 2026
Faron Pharmaceuticals Ltd: Notice To The Extraordinary General Meeting
February 11, 2026
New Review Published in Immunotherapy Highlights the Potential for Clever-1 Inhibition with bexmarilimab to Become the Cornerstone of Next-Generation, Multi-Indication Cancer Immunotherapy
January 29, 2026
Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma
January 27, 2026
←
Previous Page
1
2
3
4